Cellmid 2018 Annual Report 23
^ The negative share-based payment is due to a reversal of share based payment previously
recognised. Refer to equity-based compensation for details.
2017 Cash salary Employee Employee
fees entitlements entitlements Superannuation Options Total
$ $ $ $ $ $
Directors
Non-executive directors
David King 65,000 - - 6,175 - 71,175
Bruce Gordon 50,000 - - - - 50,000
Fintan Walton 50,000 - - - - 50,000
Total non-executive directors 165,000 - - 6,175 - 171,175
Executive directors and key management
Maria Halasz 428,538 18,457 4,470 22,800 (52,781)^ 421,484
593,538 18,457 4,470 28,975 (52,781) 592,659
Post-
Long-term employment Share-based
Short-term benefits benefits benefits payments
Directors’ and Key Management Personnel (KMP) shareholdings
The number of shares held in the Group during the financial year by each Director and (KMP) of Cellmid Limited, including their
related parties, are set out below.
*On 23 November 2017, the Group completed a twenty to one share consolidation.
Balance at Received Other Other Balance
beginning as part of changes Pre changes Post at end of
of year remuneration Consolidation Consolidation* Consolidation year
2018
David King 24,000,000 - 4,000,000 (26,600,000) - 1,400,000
Maria Halasz 25,073,025 - 2,250,000 (25,956,874) 207,500 1,573,651
Bruce Gordon 1,500,000 - - (1,425,000) - 75,000
Fintan Walton 800,000 - 500,000 (1,235,000) - 65,000
Martin Cross - - 900,000 (855,000) - 45,000
Dennis Eck - - - - 2,700,000 2,700,000
2017
David King 22,500,000 - 1,500,000 - - 24,000,000
Maria Halasz 24,222,600 - 850,425 - - 25,073,025
Bruce Gordon 500,000 - 1,000,000 - - 1,500,000
Fintan Walton 300,000 - 500,000 - - 800,000